synimmune.de bewertung und analyse
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
Meta Tags
| Title | SYNIMMUNE GmbH: |
| Description | SYNIMMUNE GmbH is a biotechnology company focusing on the development of novel mono- and bispecific antibodies for improved immunotherapy |
| Keywords | SYNIMMUNE, bispecific, antibody, monoclonal, therapeutic, immunotherapy, hematopoietic |
Server Information
| WebSite | |
| Host IP | 185.15.195.231 |
| Location | Germany |
Mehr zu entdecken
synimmune.de bewertung
|
Euro€2,204
Zuletzt aktualisiert: 2022-07-01 23:58:26
synimmune.de hat Semrush globalen Rang von 14,045,085. synimmune.de hat einen geschätzten Wert von € 2,204, basierend auf seinen geschätzten Werbeeinnahmen. synimmune.de empfängt jeden Tag ungefähr 551 einzelne Besucher. Sein Webserver befindet sich in Germany mit der IP-Adresse 185.15.195.231. Laut SiteAdvisor ist synimmune.de sicher zu besuchen. |
Verkehr & Wertschätzungen
| Kauf-/Verkaufswert | Euro€2,204 |
| Tägliche Werbeeinnahmen | Euro€56,753 |
| Monatlicher Anzeigenumsatz | Euro€19,285 |
| Jährliche Werbeeinnahmen | Euro€1,653 |
| Tägliche eindeutige Besucher | 551 |
| Hinweis: Alle Traffic- und Einnahmenwerte sind Schätzungen. | |
DNS Records
| Host | Type | TTL | Data |
| synimmune.de. | A | 86398 | IP: 185.15.195.231 |
| synimmune.de. | NS | 86400 | NS Record: b.ns14.net. |
| synimmune.de. | NS | 86400 | NS Record: d.ns14.net. |
| synimmune.de. | NS | 86400 | NS Record: c.ns14.net. |
| synimmune.de. | NS | 86400 | NS Record: a.ns14.net. |
| synimmune.de. | MX | 86400 | MX Record: 50 mx4.agenturserver.de. |
| synimmune.de. | MX | 86400 | MX Record: 10 mx2.agenturserver.de. |
| synimmune.de. | MX | 86400 | MX Record: 10 mx1.agenturserver.de. |
| synimmune.de. | MX | 86400 | MX Record: 20 mx3.agenturserver.de. |
HtmlToTextCheckTime:2022-07-01 23:58:26
| Skip to navigation Skip to content Welcome NEWS Company Management Board Advisory Board Investors Technology Fc-optimized antibodies Bispecific antibodies SYNIMMUNE’s Bispecific Antibody Platform Products Product Pipeline FLYSYN TACSYN Partnering Home » Welcome Welcome to SYNIMMUNE SYNIMMUNE GmbH is a biotechnology company dedicated to the development of innovative and effective mono- and bispecific anti-tumor antibodies for the treatment of patients suffering from life-threatening diseases, with a focus on orphan hematopoietic malignancies. SYNIMMUNE’s lead product candidate is the antibody FLYSYN, which is currently in a first-in-human phase I clinical study in acute myeloid leukemia (AML). SYNIMMUNE GmbH is a spin-off of the Department of Immunology of the University of Tuebingen. The Company is financed by grants from the German Ministry of Education and Research (BMBF) within its GO-Bio program as well as investments by the German KfW and private equity. For AML Patients |
HTTP Headers
HTTP/1.1 301 Moved Permanently Date: Wed, 27 Oct 2021 16:51:27 GMT Server: Apache Set-Cookie: fe_typo_user=04916b7bc95c83e3843687cbfd400adc; path=/ Upgrade: h2,h2c Connection: Upgrade Location: https://www.synimmune.de/ Content-Type: text/html HTTP/2 301 date: Wed, 27 Oct 2021 16:51:27 GMT server: Apache set-cookie: fe_typo_user=df90f62908c8c05a8d06a84d8adb9a21; path=/ location: https://www.synimmune.de/welcome/ content-type: text/html HTTP/2 200 date: Wed, 27 Oct 2021 16:51:28 GMT server: Apache expires: Wed, 27 Oct 2021 23:45:26 GMT cache-control: max-age=24838 pragma: public set-cookie: fe_typo_user=b011f3f0d04dea27730c7c95297c27b0; path=/ last-modified: Wed, 15 Sep 2021 10:55:57 GMT etag: "1b7cc448c7bc80be110ddf5ad2c6fed4" content-type: text/html; charset=utf-8 |